Blood Cancers

Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.

There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma.

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.

As we observe World Cancer Day, I’m reflecting on my own family’s experience with blood cancer.

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

Dr. Richard “Rick" Winneker discussed advice that he would provide to patients faced with a myeloproliferative neoplasm diagnosis.

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received at least two prior lines of therapy.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

From Gerry Turner announcing he has cancer to the return of a Chicago Cubs legend’s disease, here’s what’s happening in the cancer space this week.

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Researchers have found an increased frequency of severe maternal morbidity and obstetric complications among women who received a diagnosis of a hematological malignancy during pregnancy.

The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.

Having myelodysplastic syndromes has taught me to cherish every day and to pursue the things that matter to me, like publishing a book I’ve been writing.

For patients with MDS, close monitoring by doctors may help determine the appropriate timing to undergo stem cell transplants before the disease worsens.

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.